Your AI-Trained Oncology Knowledge Connection!

Thomas Powles, MD

Articles

Dr Powles on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer

January 16th 2024

Thomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.

Future Directions in the Management of Renal Cell Carcinoma

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

November 3rd 2022

Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.

Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 27th 2022

Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.

Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 27th 2022

Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

Thomas Powles, MD;Rana R. McKay, MD;Vaishali Sanchorawala, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 20th 2022

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 6th 2022

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

October 6th 2022

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

September 29th 2022

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

Thomas Powles, MD;Rana R. McKay, MD;Ulka Vaishampayan, MD;Eric Jonasch, MD;Benjamin Maughan, MD

September 29th 2022

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

Thomas Powles, MD

November 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

Thomas Powles, MD

July 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).